Laboratory Co. of America Holdings (NYSE:LH - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for Laboratory Co. of America in a research note issued on Thursday, February 6th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings per share of $3.67 for the quarter, down from their previous estimate of $3.84. The consensus estimate for Laboratory Co. of America's current full-year earnings is $15.96 per share. Leerink Partnrs also issued estimates for Laboratory Co. of America's Q4 2025 earnings at $4.14 EPS, FY2025 earnings at $16.09 EPS, FY2027 earnings at $19.88 EPS and FY2028 earnings at $22.13 EPS.
Other research analysts also recently issued reports about the stock. HSBC raised shares of Laboratory Co. of America from a "hold" rating to a "buy" rating in a research note on Wednesday, October 30th. Hsbc Global Res upgraded shares of Laboratory Co. of America from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 30th. Evercore ISI upgraded shares of Laboratory Co. of America from an "in-line" rating to an "outperform" rating and boosted their target price for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Bank of America boosted their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a "buy" rating in a report on Friday, December 13th. Finally, Morgan Stanley boosted their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an "overweight" rating in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Laboratory Co. of America presently has a consensus rating of "Moderate Buy" and an average target price of $265.31.
Check Out Our Latest Stock Report on LH
Laboratory Co. of America Trading Up 1.7 %
Shares of NYSE LH traded up $4.16 during mid-day trading on Monday, hitting $245.31. The stock had a trading volume of 485,466 shares, compared to its average volume of 609,361. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. Laboratory Co. of America has a 1 year low of $191.97 and a 1 year high of $258.59. The business has a 50 day moving average price of $236.92 and a two-hundred day moving average price of $230.55. The firm has a market cap of $20.52 billion, a P/E ratio of 27.81, a price-to-earnings-growth ratio of 1.84 and a beta of 1.07.
Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%.
Laboratory Co. of America Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America's payout ratio is 32.65%.
Insiders Place Their Bets
In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,121 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the sale, the chief executive officer now directly owns 86,445 shares of the company's stock, valued at $21,146,175.90. This trade represents a 6.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dwight Gary Gilliland sold 1,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $241.00, for a total transaction of $241,000.00. Following the sale, the director now directly owns 7,712 shares of the company's stock, valued at approximately $1,858,592. This trade represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,504 shares of company stock worth $5,905,692. Company insiders own 0.85% of the company's stock.
Institutional Investors Weigh In On Laboratory Co. of America
Institutional investors have recently added to or reduced their stakes in the stock. Private Trust Co. NA grew its holdings in shares of Laboratory Co. of America by 3.2% in the third quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company's stock valued at $300,000 after purchasing an additional 41 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Laboratory Co. of America by 0.5% in the fourth quarter. Empowered Funds LLC now owns 8,025 shares of the medical research company's stock valued at $1,840,000 after purchasing an additional 43 shares in the last quarter. SP Asset Management LLC grew its holdings in shares of Laboratory Co. of America by 0.3% in the fourth quarter. SP Asset Management LLC now owns 15,186 shares of the medical research company's stock valued at $3,483,000 after purchasing an additional 43 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of Laboratory Co. of America by 0.4% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 12,780 shares of the medical research company's stock valued at $2,931,000 after purchasing an additional 45 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in shares of Laboratory Co. of America by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 7,194 shares of the medical research company's stock valued at $1,650,000 after purchasing an additional 46 shares in the last quarter. 95.94% of the stock is owned by hedge funds and other institutional investors.
Laboratory Co. of America Company Profile
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Featured Stories
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
